86. 肺動脈性肺高血圧症 Pulmonary arterial hypertension Clinical trials / Disease details


臨床試験数 : 1,205 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-001411-20-GB
(EUCTR)
12/01/201809/01/2017Long-term extension study of the safety and pharmacokinetics of QCC374 in PAH patientsLong-term, open label, multicenter, extension study to evaluate the safety and tolerability of QCC374 in patients with PAH Pulmonary arterial hypertension
MedDRA version: 20.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: QCC374 0.015 mg
INN or Proposed INN: TBD
Product Code: QCC374 0.06 mg
INN or Proposed INN: TBD
Novartis Pharma AGNULLNot RecruitingFemale: yes
Male: yes
38Phase 2United States;Taiwan;Germany;United Kingdom;Korea, Republic of
2EUCTR2016-001411-20-DE
(EUCTR)
17/10/201707/08/2017Long-term extension study of the safety and pharmacokinetics of QCC374 in PAH patientsLong-term, open label, multicenter, extension study to evaluate the safety and tolerability of QCC374 in patients with PAH Pulmonary arterial hypertension
MedDRA version: 20.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: QCC374 0.015 mg
INN or Proposed INN: TBD
Product Code: QCC374 0.06 mg
INN or Proposed INN: TBD
Novartis Pharma AGNULLNot Recruiting Female: yes
Male: yes
38 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited States;Taiwan;Germany;United Kingdom;Korea, Republic of
3EUCTR2016-001412-38-DE
(EUCTR)
27/07/201703/04/2017Safety, pharmacokinetics and efficacy study of QCC374 in PAH patientsA randomized, parallel-group, placebo-controlled subject and investigator blinded study to assess the safety, tolerability, pharmacokinetics and efficacy of QCC374 in the treatment of pulmonary arterial hypertension Pulmonary arterial hypertension
MedDRA version: 20.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: QCC374 0.015 mg
INN or Proposed INN: TBD
Product Code: QCC374 0.06 mg
INN or Proposed INN: TBD
Novartis Pharma AGNULLNot RecruitingFemale: yes
Male: yes
38Phase 2United States;Taiwan;Germany;United Kingdom;Korea, Republic of